We were delighted to catch up with Dr Pinkal Desai (Weill Cornell Medical College, New York City, NY, USA) to discuss the report from the American Society of Hematology Research Collaborative (ASH RC) Data Hub on clinical predictors of outcome in adult patients with acute leukemias and myelodysplastic syndrome and COVID-19 infection.
1. Prior to your study, what was known about outcomes with COVID-19 in patients with acute myeloid leukemia, acute lymphocytic leukemia and myelodysplastic syndromes? 00:13-01:35
2. What were the aims and methodology of your study? 01:35-03:08
3. What were the findings in terms of COVID-19 severity? 03:08-04:20
4. What were the findings in terms of COVID-19 mortality? 04:20-07:32
5. What recommendations would you suggest based on these findings? 07:32-10:00
Speaker Disclosure: Pinkal Desai has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 63rd ASH Annual Meeting & Exposition
Share this Video
Related Videos In Leukaemia
Robin Foà, EHA 2023: José Carreras Award presentation – research on Philadelphia-positive acute lymphoblastic leukaemia
Each year, the EHA Board presents the José Carreras Award to honour leaders in haematological research. touchONCOLOGY caught up with Prof Robin Foà (Sapienza University, Rome, Italy) to discuss his receipt of the José Carreras Award and the key take-home messages of his award presentation, which focused on Philadelphia-positive acute lymphoblastic leukaemia research. The presentation […]
Robin Foà, EHA 2023: New developments in the treatment of Philadelphia-positive acute lymphoblastic leukaemia
The management of patients with Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL) has evolved over the last few decades, with new and exciting treatments becoming increasingly available. We caught up with Prof Robin Foà (Sapienza University, Rome, Italy) to discuss the history of Ph+ ALL research and top trials in the treatment of Ph+ ALL. The […]
Arnon Kater, EHA 2023: MURANO substudy analysis: Venetoclax-rituximab in patients with chronic lymphocytic leukaemia
The phase III MURANO trial (NCT02005471) reported that venetoclax plus rituximab (venR) resulted in higher progression-free survival and overall survival than bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukaemia. The unmet needs in the treatment of chronic lymphocytic leukaemia, as well as the aims, main findings and clinical significance of the final MURANO […]